{"id":55296,"date":"2026-01-23T15:06:17","date_gmt":"2026-01-23T07:06:17","guid":{"rendered":"https:\/\/flcube.com\/?p=55296"},"modified":"2026-01-23T15:06:18","modified_gmt":"2026-01-23T07:06:18","slug":"novo-nordisk-expands-aspect-biosystems-partnership-for-diabetes-cell-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55296","title":{"rendered":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE:\u202fNVO<\/a>) and Canadian biotechnology firm <strong>Aspect Biosystems<\/strong> announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s <strong>stem cell-derived islet cells and hypoimmunogenic cell engineering technologies<\/strong>, and will lead development, manufacturing, and commercialization efforts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-terms\">Partnership Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Novo Nordisk (NYSE:\u202fNVO) \/ Aspect Biosystems<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Expanded collaboration for cellular medicines<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Diabetes (Type\u202f1 and potentially Type\u202f2)<\/td><\/tr><tr><td><strong>Technology Licensed<\/strong><\/td><td>Stem cell-derived islet cells + hypoimmunogenic cell engineering<\/td><\/tr><tr><td><strong>Development Leadership<\/strong><\/td><td>Aspect leads development, manufacturing, and commercialization<\/td><\/tr><tr><td><strong>Novo Nordisk Rights<\/strong><\/td><td>Retains options to expand involvement in later development\/commercialization stages<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Additional equity investment + research funding; Novo Nordisk receives royalties and milestones<\/td><\/tr><tr><td><strong>Collaboration History<\/strong><\/td><td>Partnership initiated in 2023<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Disease-modifying therapies through replacement, repair, or supplementation of biological function<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-innovation\">Technology Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stem Cell-Derived Islet Cells:<\/strong> Provides renewable source of insulin-producing beta cells for transplantation<\/li>\n\n\n\n<li><strong>Hypoimmunogenic Engineering:<\/strong> Reduces risk of immune rejection, potentially eliminating need for chronic immunosuppression<\/li>\n\n\n\n<li><strong>Manufacturing Platform:<\/strong> Aspect\u2019s bioprinting and tissue engineering capabilities enable scalable, consistent production<\/li>\n\n\n\n<li><strong>Clinical Potential:<\/strong> Aims to restore physiological glucose control, offering functional cure rather than chronic disease management<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Diabetes Market:<\/strong> Valued at <strong>$80\u202fbillion<\/strong> in 2025, with cell therapy segment growing at <strong>25% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Despite insulin advances, only cell therapy offers potential cure for Type\u202f1 diabetes; <strong>1.5\u202fmillion<\/strong> new Type\u202f1 cases diagnosed annually<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>$5\u20138\u202fbillion<\/strong> peak sales potential for successful diabetes cell therapy<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Novo Nordisk\u2019s continued investment validates Aspect\u2019s platform and positions both companies as leaders in regenerative medicine<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Establishes Aspect as the primary development partner for next\u2011generation diabetes cell therapies while strengthening Novo Nordisk\u2019s pipeline<\/li>\n\n\n\n<li><strong>Timeline:<\/strong> Clinical trial initiation expected in <strong>2027<\/strong>; first regulatory submissions targeted for <strong>2029<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development timelines, clinical outcomes, and revenue potential for the diabetes cellular medicine program. Actual results may differ due to clinical trial risks, regulatory pathways, and competitive dynamics in the cell therapy market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,39,148,860],"class_list":["post-55296","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-diabetes","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55296\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55296\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-23T07:06:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T07:06:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy\",\"datePublished\":\"2026-01-23T07:06:17+00:00\",\"dateModified\":\"2026-01-23T07:06:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Diabetes\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55296#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55296\",\"name\":\"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-23T07:06:17+00:00\",\"dateModified\":\"2026-01-23T07:06:18+00:00\",\"description\":\"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55296\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55296#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55296","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy","og_description":"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.","og_url":"https:\/\/flcube.com\/?p=55296","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-23T07:06:17+00:00","article_modified_time":"2026-01-23T07:06:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55296#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55296"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy","datePublished":"2026-01-23T07:06:17+00:00","dateModified":"2026-01-23T07:06:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55296"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Diabetes","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55296#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55296","url":"https:\/\/flcube.com\/?p=55296","name":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-23T07:06:17+00:00","dateModified":"2026-01-23T07:06:18+00:00","description":"Novo Nordisk (NYSE:\u202fNVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their collaboration to develop advanced cellular medicines for diabetes. Under the expanded agreement, Aspect secures rights to Novo Nordisk\u2019s stem cell-derived islet cells and hypoimmunogenic cell engineering technologies, and will lead development, manufacturing, and commercialization efforts.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55296#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55296"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55296#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55296"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55296\/revisions"}],"predecessor-version":[{"id":55298,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55296\/revisions\/55298"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}